Ensem Therapeutics is a drug discovery and development company focused on oncology. It integrates computational and AI deep learning methodologies with experimental techniques to develop small-molecule precision medicines. The company develops an oral cyclin-dependent kinase 2 inhibitor as well as a molecule that targets mutant phosphoinositide 3-kinase alpha without impacting glucose homeostasis.